Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 3, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 2, 2026 — +29.7% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$920.00 – $950.00Entry zone — fair-value band

$935.58Published — price the day we called it

$1,066.56Target — the price the thesis aimed for

$1,238.00Peak — highest point inside the window, not a realized return

$1,213.91Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 49 days.

At window close

+29.7%

realized, from the publication price to the last close inside the window

Peak gain

+32.3%

peak, from the publication price — not a realized return

S&P 500, same window

+13.9%

SPY over the identical days, dividend-adjusted

Window close

$1,213.91

last close inside the window, ended July 2, 2026

Peak price

$1,238.00

peak on June 29, 2026 — not a realized return

Days to target

The thesis — published April 3, 2026

Predicted growth

+14%

over the measurement window

Target price

$1,066.56

the price the thesis aimed for

Entry zone

$920.00 – $950.00

the fair-value band we waited for

Price at publication

$935.58

published April 3, 2026

Confidence

81%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Lilly looks well positioned for the next few months because its weight-loss and diabetes businesses keep driving sales while the stock has eased to a calmer level. The company added new assets through an acquisition, but competitor headlines could raise expectations. Overall, the price is near the recent average, so the setup appears constructive rather than frothy.

Primary drivers

Obesity and diabetes products keep steady customer demand
Acquisition adds new drug candidates and strengthens the pipeline
Competitor headlines add pressure but do not derail growth potential
Stock price is near the recent average price, showing stability

How it played out

LLY: target reached in 49 days

Lyra published a short-term thesis at 935.58, expecting 14% growth toward 1066.56. The thesis pointed to steady demand for obesity and diabetes products, new drug candidates from an acquisition, pressure from competitor headlines, and a share price near its recent average. It described the setup as constructive rather than overheated.

Inside the window, shares reached the target in 49 days. The price later peaked at 1238 on June 29, a 32.3% gain, and ended at 1213.91 on July 2. Both the peak and closing price were above the target. The published thesis played out and exceeded its stated objective.

What happened during the window

On April 30, Lilly reported its first-quarter 2026 results and raised its full-year guidance. On May 6, the company announced an additional $4.5 billion investment across two Indiana manufacturing sites.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals